In this issue:
- Sudden cardiac death and myocardial fibrosis in HIV
- HIV PrEP across Australian clinics
- Time spent with HIV-RNA ≤200 copies/mL in the U=U era
- Low HCV in PrEP users: contribution of sexual transmission
- Routine syphilis screening in men with HIV
- Long-term HIV protection with PrEP in gay/bisexual men
- Targeted testing and immediate initiation of acute HIV treatment in MSM
- Emtricitabine with TAF or TDF for HIV-1 PrEP
- Dolutegravir/lamivudine in test-and-treat setting for newly diagnosed HIV
- COVID vaccination (AstraZeneca) in patients with HIV
Please login below to download this issue (PDF)